Comparing the current results to its competitors, Corcept Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 31.74 % year on year. The sales growth was above Corcept Therapeutics Inc's competitors' average revenue growth of 7.7 %, achieved in the same quarter.
Corcept Therapeutics Inc's Comment on Competition and Industry Peers
The company's products compete with established treatments for Cushing's syndrome, including surgery, radiation, and FDA-approved medications such as Signifor® (pasireotide), Isturisa® (osilodrostat), and Recorlev®. Signifor and Isturisa are marketed by Recordati S.p.A, while Recorlev is marketed by Xeris Biopharma Holdings, Inc. The products also compete with off-label drugs such as ketoconazole and metyrapone. Since January 2024, competition has included a generic version of Korlym sold by Teva Pharmaceuticals USA, Inc. The company holds patents related to its next-generation cortisol modulators and selective cortisol modulators, with expiration dates ranging from 2028 to 2042. Although the composition of matter patent for Korlym’s active ingredient, mifepristone, has expired, the company retains method of use patents. Orphan drug exclusivity may provide additional market protection, subject to future legal and regulatory developments.
September 23, 2025
: Recent developments from Corcept Therapeutics highlight promising advancements in the treatment of both platinum-resistant ovarian cancer and amyotrophic lateral sclerosis (ALS). Comprehensive analyses from the Phase 3 ROSELLA study and the Phase 2 DAZALS study, presented at the European Society for Medical Oncology (ESMO) 2025 and the European Network to Cure ALS (ENCALS) 2025 Annual Meeting, respectively, illustrate the potential of Relacorilant and Dazucorilant in altering the treatment landscape for these challenging diseases.Corcept Therapeutics Incorporated (NASDAQ: CORT), based in Redwood City, California, is making significant strides in the development of therapies targeting the modulation of cort...
May 6, 2025
In the latest corporate update, Corcept Therapeutics Incorporated (NASDAQ: CORT), a pioneering force in the pharmaceutical sector, showcased strong first-quarter results for the fiscal year ending March 31, 2025. As the Redwood City-based company navigates the complexities of modern medical challenges, it continues to strengthen its foothold across multiple therapeutic disciplines, leveraging the modulation of cortisol, a hormone intricately tied to a myriad of physiological processes. Financial Performance and Market Sentiment The first quarter of 2025 marked a milestone for Corcept Therapeutics as they reported unprecedented prescription volumes, attributed to both new and longstanding prescribers. This su...
April 23, 2025
In an important development for cancer treatment, Corcept Therapeutics Incorporated is set to present data from its pivotal Phase 3 ROSELLA trial of relacorilant in combination with nab-paclitaxel for patients suffering from platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The announcement highlights both the urgency and innovation surrounding therapies for a cancer subtype notorious for its poor prognosis and limited treatment options.Ovarian cancer remains a significant challenge for clinicians, particularly when it progresses to the platinum-resistant state, meaning that standard chemotherapy treatments, notably those based on platinum compounds li...
January 1, 2025
In the world of biotech, innovation often walks a tightrope, balancing the exhilarating promise of breakthroughs with the sobering validation of regulatory hurdles. As Corcept Therapeutics Incorporated takes bold steps forward, it stands as a testament to the resilience and creativity that defines this dynamic sector. Recently, the Redwood City-based company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its groundbreaking treatment, Relacorilant, aimed at tackling the often debilitating condition known as endogenous hypercortisolism.Relacorilant is more than just a compound in development; it represents a meticulous understanding of cortisol the hormone that govern...
December 13, 2024
In a significant development for the management of hypercortisolism, commonly known as Cushing s syndrome, Corcept Therapeutics Incorporated recently announced the successful achievement of the primary endpoint in the treatment phase of its CATALYST trial. This randomized, double-blind, placebo-controlled study investigated the efficacy of Korlym (mifepristone), a medication designed to modulate the effects of cortisol, in patients with hypercortisolism accompanied by challenging diabetes control.Cushing s syndrome is characterised by prolonged exposure to excess cortisol levels, resulting from various factors, including adrenal tumours, pituitary adenomas, or ectopic ACTH production. The disorder is often a...
December 12, 2024
Corcept Therapeutics Advances in ALS Research with Promising Phase 2 Study Results and Robust Financial Performance In a noteworthy development for the medical community and patients affected by neurodegenerative diseases, Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company specializing in innovative treatments for severe endocrinologic, oncologic, metabolic, and neurologic disorders, has announced compelling results from its recent Phase 2 clinical trial. The DAZALS study evaluated the efficacy and safety of Dazucorilant, a selective cortisol modulator, in patients diagnosed with amyotrophic lateral sclerosis (ALS), a debilitating and currently incurable neurodegenerative disease. P...
June 3, 2024
Relacorilant Shows Positive Results in Phase 3 GRACE Trial for Hypercortisolism MENLO PARK, Calif., June 03, 2024 - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage biopharmaceutical company specializing in the discovery and development of medications that modulate the effects of the hormone cortisol, recently announced the presentation of results from its pivotal Phase 3 GRACE trial. The study evaluated the efficacy and safety of relacorilant in patients with hypercortisolism, commonly known as Cushing s syndrome. Background on Hypercortisolism (Cushing s Syndrome) Hypercortisolism, or Cushing s syndrome, is a hormonal disorder caused by prolonged exposure to elevated levels of cortiso...
May 28, 2024
In a significant step forward for Corcept Therapeutics Incorporated, the Phase 3 clinical trial of their experimental drug, relacorilant, has successfully achieved its primary endpoint. The medication has shown promising results in effectively treating hypercortisolism, a condition commonly known as Cushings syndrome. This exciting development brings new hope to patients suffering from this debilitating hormonal disorder. Let s delve into the key details of this breakthrough and analyze its impact on the company and the medical community.Key Findings from the Phase 3 GRACE Trial:Corcept Therapeutics Incorporated recently revealed that the Phase 3 trial for relacorilant, their selective cortisol modulator, ha...
April 29, 2024
Corcept, widely acclaimed for its novel approach in curbing diverse disorders by modulating the effects of the hormone cortisol, has completed enrollment for the fourth phase of its CATALYST trial. The trial aims to estimate the prevalence of hypercortisolism (commonly known as Cushing’s syndrome) in patients grappling with difficult-to-control type 2 diabetes. Patients diagnosed with hypercortisolism are now eligible for a randomized, placebo-controlled study of Korlym, a medication produced by Corcept.Hypercortisolism, a condition wherein the body experiences excessive amounts of cortisol, is linked to a host of health problems including diabetes, hypertension, obesity, and depression. With the CATALYST ...
April 22, 2024
In the realm of pharmaceutical sciences, groundbreaking developments can have a profound impact on patient populations suffering from debilitating endocrine disorders. Corcept Therapeutics Incorporated, a prominent player in this field, has recently revealed positive findings from the open-label portion of the Phase 3 GRACE trial. This pivotal study involved evaluating the efficacy of the selective cortisol modulator, relacorilant, in patients with various underlying causes of endogenous Cushings syndrome (hypercortisolism). The results of this trial, which exemplify the potential of relacorilant as a therapeutic breakthrough, hold significant implications for the company and its ongoing efforts in treating ...
Bausch Health Companies Inc operates through three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. The company focuses on developing, manufacturing, and marketing a wide range of pharmaceutical products, medical devices, and over-the-counter products primarily in the areas of eye health, gastroenterology, and dermatology. Bausch Health aims to provide innovative and quality healthcare solutions to improve patients' lives globally.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing therapies to treat autoimmune diseases such as lupus nephritis. Their business model revolves around conducting research and development to bring innovative medications to the market, securing partnerships and collaborations with other companies, and generating revenue through the sales of their products. By leveraging their expertise in the field, Aurinia aims to improve the lives of patients suffering from these diseases and achieve financial success through the commercialization of their therapies.
Aquestive Therapeutics Inc follows a business model that focuses on the development and commercialization of innovative products to address unmet medical needs. The company primarily operates in the pharmaceutical industry, leveraging its proprietary drug delivery technology to create and improve various medications for patients.
Amneal Pharmaceuticals Inc operates as a fully integrated pharmaceutical company, primarily focused on the development, manufacturing, and distribution of generic and specialty pharmaceutical products. Their business model revolves around identifying market opportunities, conducting research to develop cost-effective formulations, and leveraging their expansive manufacturing capabilities to produce and distribute a wide range of pharmaceuticals to customers globally. Additionally, they aim to provide high-quality products at competitive prices while continuously investing in research and development to expand their product portfolio.
Sources:
Corcept Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Corcept Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
